Premium
Successful recovery from severe COVID‐19 pneumonia after kidney transplantation: The interplay between immunosuppression and novel therapy including tocilizumab
Author(s) -
Lauterio Andrea,
Valsecchi Mila,
Santambrogio Sara,
De Carlis Riccardo,
Merli Marco,
Calini Angelo,
Centonze Leonardo,
Buscemi Vincenzo,
Bottiroli Maurizio,
Puoti Massimo,
Fumagalli Roberto,
De Carlis Luciano
Publication year - 2020
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1111/tid.13334
Subject(s) - medicine , immunosuppression , tocilizumab , hydroxychloroquine , pneumonia , lopinavir , ritonavir , kidney transplantation , lopinavir/ritonavir , covid-19 , transplantation , immunology , intensive care medicine , human immunodeficiency virus (hiv) , viral load , rheumatoid arthritis , antiretroviral therapy , disease , infectious disease (medical specialty)
Although immunosuppressed patients may be more prone to SARS‐CoV‐2 infection with atypical presentation, long‐term immunosuppression therapy may provide some sort of protection for severe clinical complications of COVID‐19. The interaction between immunosuppression and new antiviral drugs in the treatment of transplanted patients contracting COVID‐19 has not yet been fully investigated. Moreover, data regarding the optimal management of these patients are still very limited. We report a case of the successful recovery from severe COVID‐19 of a kidney‐transplanted patient treated with hydroxychloroquine, lopinavir/ritonavir, steroid, and tocilizumab.